Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
NCT05292404Phase 4Recruiting
- Sponsor
- Shanghai Tongren Hospital
- Start
- Oct 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of alirocumab in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by Shanghai Tongren Hospital. Primary endpoint: Myocardial Salvage Index at 1 week. Started Oct 2022; status: recruiting.
02
Drugs
alirocumab
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT05292404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05292404.